QIAGEN appoints Dr. Thomas Schweins as Vice President Corporate Strategy
Venlo, The Netherlands, February 17, 2004 - QIAGEN, N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) today announced that Dr. Thomas Schweins has joined QIAGEN and will assume responsibility for QIAGEN's development and long-term corporate strategy worldwide as Vice President Corporate Strategy starting February 1, 2004. Dr. Schweins will be a member of the Executive Committee of QIAGEN, based in QIAGEN's European headquarters in Hilden. He will report to Peer M. Schatz, QIAGEN's Chief Executive Officer.
Dr. Schweins brings to QIAGEN more than eight years of industry and executive experience. He joins QIAGEN from The Boston Consulting Group, Düsseldorf, where he was Manager and core team member of the Pharma/Health Care as well as the Corporate Development Practice Area. In this position he was responsible for strategy projects in the Biotech, MedTech and Pharma industry. Prior to his latest position with BCG, Dr. Schweins worked three years as Technology Manager and as Assistant to the Board with Hoechst/Aventis. At Hoechst he was involved in, among other things, technology scouting activities, the formation of a Corporate Venture Capital Fund, and Hoechst's strategy in the field of biotechnology.
Dr. Schweins earned a biochemistry degree from the University of Hanover. He obtained his Ph.D. at the Max-Planck-Society and received a M.Sc. from the University of Southern California, LA where he studied business administration and chemistry. In 1994 Dr. Schweins received the Otto-Hahn-Medal from the Max-Planck-Society for his work in the field of protein science and oncology.
In his newly created position as QIAGEN's Vice President Corporate Strategy, Dr. Schweins will be responsible for development, implementation and monitoring of QIAGEN's long-term strategy and market development activities. His responsibility also include a definition of QIAGEN`s licensing and acquisition strategy as well as the coordination and monitoring of QIAGEN's application portfolio.
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
Peer M. Schatz
Dr. Solveigh Mähler